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Background/Aims:  The  prevalence  of  diabetes  in  Korea  is  reported  to  be  approximately  10%,  but  cases  of 
maturity-onset diabetes of the young (MODY) are rare in Korea. A diagnostic technique for autosomal dominant MODY 
is being actively sought. In this regard, we used a DNA chip to investigate the frequency of mutations of the MODY3 
gene  (hepatocyte  nuclear  factor-1α)  in    Korean  patients  with  early-onset  type  2  diabetes.
Methods: T h e  g e n o mi c  D N A  o f  3 0  n o r ma l  i n d i v i d u a l s  [ a g e ,  2 4 . 9 ±8 . 6  y e a r s ]  a n d  2 5  p a t i e n t s  w i t h  e a r l y - o n s e t  t y p e  
2 diabetes (age, 27±5.9 years) was extracted, and the MODY3 gene was amplified. The amplified DNA was hybridized 
onto a MODY3 chip, which has oligonucleotides of 15-25 bases, representing wild-type and mutant MODY3 sequences 
in  both  forward  and  reverse  orientations,  immobilized  on  its  surface.
Results: A m o n g  t h e  n o r m a l  s u b j e c t s ,  t h e r e  w a s  n o  m u t a t i o n  o f  M O D Y 3 .  A m o ng  those  with  early-onset  type  2 
diabetes,  there  was  one  case  of  MODY3  mutation.
Conclusions: Our results indicate that MODY3 mutations are not rare in Korean early-onset type 2 diabetes patients in 
Korea  and  suggest  that  MODY3  mutations  in  patients  with  early-onset  type  2  diabetes  need  to  be  further  evaluated. 
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INTRODUCTION
The  prevalence  of  diabetes  in  Korea  is  reported  to  be 
approximately  10%  and  most  patients  have  type  2  diabetes 
mellitus
1).  M a t u r i t y - o n s e t  d i a b e t e s  o f  t h e  y o u n g  ( M O D Y )  i s  a  
heterogeneous  form  of  diabetes  characterized  by  onset  at  an 
early  age,  impaired  insulin  secretion,  and  inheritable  as  an 
autosomal  dominant  trait  for  more  than  three  generations. 
M O D Y  h a s  n u m e r o u s  s u b t y p e s ,  d e p e n d i n g  u p o n  t h e  g e n e  
that  is  involved:  MODY1  is  associated  with  chromosome  20; 
MODY2,  with  chromosome  7;  MODY3,  with  chromosome  12; 
MODY4,  with  chromosome  13;  MODY5,  with  chromosome  17; 
and  MODY6,  with  chromosome  2.  The  MODY3  gene  encodes 
hepatocyte  nuclear  factor  (HNF)-1α,  which  is  a  homeodomain- 
containing  transcription  factor  required  for  tissue-specific 
expression  of  a  variety  of  genes  in  the  liver,  kidney,  pancreas 
(including  the  Islets  of  Langerhans),  intestine,  stomach,  spleen, 
and  thymus
2, 3).  Although  mutations  of  the  MODY2  gene 
(glucokinase) are the most common mutations in French MODY 
p a t i e n t s ,  M O D Y 3  ( H N F - 1 α )  m u t a t i o n s  a r e  t h e  m o s t  c o m m o n  
mu t a t i ons  i n  We s t e r n a nd As i a n c ount r i e s
4-7).  Nevertheless,  only 
a  few  cases  of  MODY  have  been  reported  in  Korea. 
Diagnostic  techniques  for  autosomal  dominant  MODY  are 
currently  being  sought.  In  this  study,  we  used  a  DNA  chip  to 
investigate  the  frequency  of  MODY3  mutations  in  Korean 
patients  with  early-onset  type  2  diabetes.The  Korean  Journal  of  Internal  Medicine:  Vol.  23,  No.  4,  December  2008 166
Variables Normal  group  (n=30) Diabetes  group  (n=25)
Age  (years)
Gender,  male
BMI  (kg/m
2)
SBP  (mmHg)
DBP  (mmHg)
Fasting  glucose  (mg/dL)
2-h  glucose  (mg/dL)
Total  cholesterol  (mg/dL)
Triglyceride  (mg/dL)
HDL  cholesterol  (mg/dL)
LDL  cholesterol  (mg/dL)
Basal  C-peptide  (ng/mL)
*2-h  C-peptide  (ng/mL)
24.9±8.6
17  (57%)
22.5±3.0
121.2±11.1
70.3±11.3
93.8±11.2
128±9.4
173.4±48.3
124.8±110.7
52.6±11.3
96.6±40.7
2.3±2.5
3.8±2.6
27.0±5.9
13  (52%)
24.0±3.2
135.6±15.7
78.0±11.9
145.0±70.9
299.2±90.1
170.1±51.0
163.6±99.7
40.9±9.7
96.9±48.3
3.6±4.5
4.2±2.9
S B P ,  s y s t o l i c  b l o o d  p r e s s u r e ;  D B P ,  d i a s t o l i c  b l o o d  p r e s s u r e ;  H D L,  high-density  lipoprotein;  LDL,  low-density  lipoprotein;  *level  after  a 
75-g  oral  glucose  tolerance  test.
Table  1.  Clinical  characteristics  and  laboratory  findings 
Site Forward Reverse
Promoter
Exon  1
Exon  2
Exon  3
Exon  4
Exon  5
Exon  6
Exon  7
Exon  8
Exon  9
Exon  10
TGGCCGTGAGCATCCTCTGCC
CGTGGCCCTGTGGCAGCCGA
CCCTTGCTGAGCAGATCCCGTC
GCAAGGTCAGGGGAATGGAC
GGCTCATGGGTGGCTATTTCTGC
TGCTGAGGCAGGACACTGCTTC
CCCGGACACAGCTTGGCTTCC
CAGGCCTGGCCTCCACGCAG
GGCCCAGTACACCCACACGGG
GGCCCAGTACACCCACACGGG
GCCTTGTTTGCCTCTGCAGTG
GCGTGGGTTGCGTTTGCCTGC
GGGCTCGTTAGGAGCTGAGGG
GGGATGGTGAAGCTTCCAGCC
CGCCGTTGTACCTATTGCACTCC
CGTGTCCCTTGTCCCCACATACC
TACAAGCAAGGACACTCACCAGC
ATCCCCACCAGCTTACCGATGAC
GGGGCTCTGCAGCTGAGCCAT
GGGCAGGGACAGTAAGGGAGG
GGGCAGGGACAGTAAGGGAGG
GGCCATCTGGGTGGAGATGAAG
Table  2.  PCR  primer  sequences  for  the  HNF-1α  gene
MATERIALS AND METHODS
Study  subjects
Thirty  normal  individuals  [age  (mean±SD),  24.9±8.6  years] 
who  had  no  family  history  of  diabetes  and  who  showed  a 
normal serum glucose level in a 75-g oral glucose tolerance test 
(OGTT) were enrolled in this study as controls. We also enrolled 
25 patients (age, 27±5.9 years) who had been diagnosed with 
early-onset diabetes before the age of 35 years
7). The diagnostic 
criteria  for  type  2  diabetes  followed  those  of  the  57
th A D A  
Conference  held  in  Boston  in  June  1997
8).  Glucose  values  of 
<110 mg/dL (6.1 mmol/L) and <140 mg/dL (7.75 mmol/L) were 
used as the normal fasting plasma glucose level and normal 2-h 
glucose  level  after  a  75-g  OGTT,  respectively.  The  normal 
C-peptide  level  was  >0.6 ng/mL.  Insulin  and  glutamic  acid 
decarboxylase  auto-antibodies  were  noted  at  diagnosis.  We 
measured the height, weight, body mass index (BMI), and blood 
pressure  for  each  subject,  and  determined  the  fasting  glucose 
l e v e l ,  g l u c o s e  l e v e l  2 - h  a f t e r  a  7 5 - g  O G T T ,  a n d  i n s u l i n  a n d  
C-peptide  levels  in  both  the  normal  and  early-onset  type  2 
diabetes  groups.
Nucleotide  sequencing
From each subject, a blood sample (4 mL) was collected into 
a tube containing EDTA. Genomic DNA was extracted from the 
whole  blood  using  a  genomic  DNA  extraction  kit  (Promega, 
Madison, WI, USA). Single or multiplex PCR amplification of the 
HNF-1α  gene  was  carried  out  using  10  different  primer  sets 
(Table 2). Direct sequencing of the PCR products was performed 
u s i n g  a n  A B I  D y e  T e r m i n a t o r  C y c l i n g  S e q u e n c i n g  k i t  ( A p p l i e d  
Biosystems,  Foster  City,  CA,  USA)  according  to  the 
manufacturer's instructions, followed by analysis on an ABI3700 
DNA  sequencer  (Applied  Biosystems)
12).
Site-directed  mutagenesis
Site-directed mutations were introduced into MODY3 DNA by 
using  a  PCR  method  and  primers  modified  for  the  specific 
mutations  (Bioneer,  Seoul,  Korea).  The  PCR  products  were 
inserted  into  plasmids,  which  were  used  to  transform  bacteria. 
The  plasmid  DNA  was  purified  using  a  commercial  kit  (Qiagen, Dong  Mee  Lim,  et  al.  HNF-1α  mutation  in  normal  and  early-onset  type  2  diabetes  patients 167
Figure  1.  Schematic  of  microspotting  the  MODY3  chip.
 
 
Figure 2. (A) Results of a MODY3 microarray analysis of DNA from a patient with type 2 diabetes and no HNF-1α promoter mutation. The white 
rectangle outlines the area of decreased signal intensity owing to the wild-type HNF-1α gene. (B) Results of a MODY3 microarray analysis of DNA 
from  a  patient w ith type 2 diabetes and a H N F-1α  prom oter m uta tion. The w hite rectangle outlines the area  of increased signa l intensity owing 
to  the  mutant  HNF-1α  promoter  sequence.
Valencia, CA, USA), and the mutations were confirmed by direct 
sequencing
13). 
PCR  and  hybridization
For  PCR,  the  reaction  mixture  contained  0.2  µg  of  either 
wild-type  or  mutant  DNA,  100  µM  of  each  dNTP  (Amersham 
Biosciences,  Uppsala,  Sweden),  and  100  nM  each  of  five 
multiplex  primer  sets:  one  set  for  mutations  in  the  promoter 
r e g i o n  a n d  e x o n s  2 ,  4 ,  a n d  7 ,  a n d  f o u r  s e t s  f o r  m u t a t i o n s  i n  
exons  1,  3,  5,  6,  8,  9,  and  10.  The  PCR  conditions  were  35 
cycles of 95℃ for 30 s, 64℃ for 15 s, and 72°C for 3 min. The 
P C R  p r o d u c t  w a s  p u r i f i e d  u s i n g  a  Q i a g e n  k i t ,  a n d  t h e  p u r i f i e d  
PCR product (A260/A550 = 1.0-3.5) was used for hybridization.
The  PCR  product  was  diluted  to  150-187.5  nM,  mixed  with 
Cy3-labeled  tag  oligonucleotide,  denatured  at  94℃  for  5  min, 
cooled on ice, and then mixed with 30 µL of hybridization buffer 
[ 6 × S S P E  ( 0 . 1 5  M  N a C l ,  1 0  m M  N a H 2PO4,  1  mM  EDTA,  pH 
8.0), 0.1% Triton X-100, 25% formamide]. A HybriWell (Molecular 
Probes,  Eugene,  OR,  USA)  was  sealed  to  a  Gen-Spector
® 
MODY3 chip (2.54 × 7.62 cm; Samsung, Yongin, Korea), which 
has oligonucleotides of 15-25 bases, representing wild-type and 
mutant  probes  in  both  forward  and  reverse  orientations, 
immobilized  on  its  surface.  Sixty  microliters  of  PCR  fragment- 
hybridization buffer mixture were added to the HybriWell through 
a hole in the sealer, the air bubbles were removed, and the hole 
was  covered  with  a  stopper.  Hybridization  was  performed  at  4
8 ℃  f o r  4  h ,  f o l l o w e d  b y  w a s h i n g  w i t h  3 × S S P E / 0 . 0 0 5 %  T r i t o n  
X-100 buffer and then 1×SSPE/0.005% Triton X-100 buffer. The 
chip  was  dried  for  15  min  at  room  temperature.
The hybridization signals were detected by scanning the array 
using a GenePix 4000B scanner (Axon Instruments, Union City, 
CA, USA), and digitized images were produced using GenePix Pro 
software (Axon) (Figure 2). The data were analyzed using a module 
of the GenSpector
® TMC-1000 system (Samsung). The probability 
that a sample represented a specific mutant was calculated using 
an  algorithm  based  on  an  MA-plot  determined  in  preliminary 
ABThe  Korean  Journal  of  Internal  Medicine:  Vol.  23,  No.  4,  December  2008 168
experiments  using  wild-type  and  mutagenized  DNA  samples.  A 
s a m p l e  w a s  c o n s i d e r e d  t o  h a r b o r  a  particular  mutation  if  the 
probability  that  the  sample  belonged  to  the  specific  mutant  was 
>99.9%. A sample was considered wild-type for the mutation if the 
probability  that  the  sample  belonged  to  the  specific  mutant  was 
<0.001%.  The  call  rate  was  95%,  and  the  remaining  5%  of  the 
spots  were  in  the  gray  zone.  The  accuracy  was  99.7%,  and  the 
reproducibility  was  99.8%.
RESULTS
In the normal group (n = 30), both the fasting serum glucose 
level (93.8±11.2 mg/dL) and the 2-h glucose level after a 75-g 
O G T T  ( 9 5 . 6 ± 2 0 . 3  m g / d L )  w e r e  n o r m a l .  T h e  i n s u l i n  l e v e l  w a s  
7.7±2.3  μIU/mL when  fasting and  33.4±25.3 μIU/mL at 2 h 
after  a  75-g  OGTT;  the  respective  C-peptide  levels  were 
2.3±2.53 and 8.5±4.6 ng/mL. These values are consistent with 
normal  insulin  secretion.
In the early-onset type 2 diabetes patients (n = 25) who were 
treated  with  oral  anti-diabetic  agents,  the  basal  C-peptide  level 
was  3.6±4.55  ng/mL,  and  the  C-peptide  level  at  2  h  after  a 
75-g  OGTT  was  7.8±8.1  ng/mL  (Table  1). 
We used DNA chips to detect mutations of the HNF-1α gene 
in patients and normal controls. No mutations were detected in 
any  control  subject.  One  patient  in  the  diabetic  group  had  a 
mut at i on ( Fi gure 2) .  Di rect  sequenci ng of  t he HNF- 1α mut at i on 
in this patient revealed a C substituted for a G in the promoter 
region  of  the  gene  (5'-ctaGGCTAGTGGGGTTTTGCGG  GGGC 
AGTGGGTGCAAGG-3').  The  patient  with  the  mutation,  a 
woman, had been diagnosed with diabetes at 25 years of age. 
Her  plasma  glucose  levels  were  151  and  273 mg/dL  prior  to 
and  2  h  after  the  intake  of  75  g  of  glucose,  respectively.  Her 
serum basal C-peptide level was 3.83 ng/mL, and her BMI was 
22  kg/m
2  at  the  time  of  diagnosis.  She  is  now  controlling  her 
diabetes  with  diet,  physical  activity,  and  metformin.  Her 
hemoglobin  A1c  level  is  being  maintained  at  6.5%.  Her 
grandmother  and  father  had  diabetes  mellitus,  but  their  blood 
samples  were  not  available  for  genotyping.
DISCUSSION
PCR  techniques  for  genetic  analysis  were  developed  in  the 
early 1990s and have enabled the identification of genes involved 
MODY. DNA microarray technology is a new automated method 
for  obtaining  large  amounts  of  information  in  a  few  hours.  The 
quick  and  accurate  diagnosis  of  disorders  caused  by  genetic 
mutations  is  an  expected  clinical  application  of  DNA  microarray 
technology.  The  development  and  application  of  DNA  chips  for 
specific genetic disorders would form the foundation of personal 
p r e v e n t i v e  m e d i c i n e .  A  D N A  c h i p  c o u l d  b e  u s e d  t o  r a p i d l y ,  
conveniently, and accurately predict the genetic predisposition of 
an  individual.  With  classical  methods  of  gene  sequencing 
analysis,  identifying  MODY  mutations  takes  more  than  3  days; 
h o w e v e r ,  w i t h  t h e  M O D Y 3  c h i p  ( F i g u r e  1 ) ,  M O D Y  c a n  b e  
diagnosed in only 0.5 days
9-11). Using a MODY3 chip, more than 
70 reported mutation sites in the HNF-1α gene can be screened 
with  >99.7%  accuracy,  using  our  in-house-developed  diagnostic 
software,  GenSpector
®  Analyzer.
MODY  accounts  for  up  to  3%  of  diabetes  cases  in  most 
Caucasian  populations
6, 14-19).  The  MODY  gene  on  chromosome 
12q  has  been  shown  to  encode  HNF-1α,  which  had  not 
p r e v i o u s l y  b e e n  k n o w n  t o  h a v e  a  r o l e  i n  t h e  f u n c t i o n i n g  o f  
pancreatic β cells. Mutations in HNF-1α (MODY3) are the most 
common cause of MODY and are thought to be the result of a 
hotspot for spontaneous  mutations  in the gene, rather than the 
result of a single distantly related family mutation. Among families 
with  a  HNF-1α  mutation,  15%  have  an  insertion  of  an  extra 
nucleotide  (C)  in  the  G  tract  in  exon  4,  which  leads  to  a 
frameshift
14, 19, 20). 
The clinical symptoms associated with HNF-1α mutations are 
markedly  different  from  those  associated  with  glucokinase 
mutations
21).  With  HNF-1α  mutations,  the  onset  of  hyper-
glycemia occurs in adolescence or early adulthood and may be 
progressive  and  more  severe,  with  more  frequent  microvascular 
complications. In contrast, with glucokinase mutations, hypergly-
cemia  begins  in  early  childhood  (from  birth)  and  is  mild,  with 
minor  age-related  deterioration;  microvascular  complications 
occur  more  rarely  than  with  HNF-1α  mutations. 
A l t h o u g h  t h e  p r e v a l e n c e  o f  M O D Y 3  h a s  b e e n  r e p o r t e d  f o r  
many  countries,  the  prevalence  of  MODY3  in  type  2  diabetes 
has  not  been  reported  for  Korea.  If  the  prevalence  and 
inheritance  of  MODY3  in  Koreans  were  known,  accurate 
diagnosis  and  treatment  may  be  possible,  and  the  risk  for 
MODY3  could  be  predicted  in  normal  individuals  born  into 
families  with  a  history  of  diabetes.  Knowledge  of  the  frequency 
of MODY3 among Koreans would aid in the accurate and early 
diagnosis of diabetes, thus minimizing diabetic complications and 
early-onset  diabetes.
In  the  present  study  with  25  early-onset  type  2  diabetes 
patients,  the  prevalence  of  HNF-1α  mutations  was  4%.  There 
have been three other reports regarding mutations of the HNF-1
α gene in Koreans. Lee et al.
7) i dent i f i ed a mut at i on i n ex on 4 
(C900A), which occurred in only one of 69 Korean subjects with 
early-onset type 2 diabetes; this mutation was silent, although it 
did  cause  an  amino  acid  substitution  at  Pro300.  Kim  et  al.
22) 
identified  the  HNF-1α  R267L  mutation  in  one  of  16  unrelated 
pa t i e n t s  who h a d be e n di a gn os e d wi t h t y pe  2 di a be t e s  a t  <35 
y e a r s  o f  a g e  a n d  w h o  h a d  a u t o s o m a l  d o m i n a n t  i n h e r i t a n c e  o f  Dong  Mee  Lim,  et  al.  HNF-1α  mutation  in  normal  and  early-onset  type  2  diabetes  patients 169
type  2  diabetes  in  at  least  two  generations.  Shin  et  al.
23) 
reported that the overall frequencies of HNF-1α and glucokinase 
gene  mutations  were  5  and  2.5%,  respectively,  in  40  Korean 
adolescent  patients  with  type  2  diabetes  and  a  strong  family 
history  of  diabetes. 
In our opinion, the prevalence of MODY3 in early-onset type 
2  diabetes  in  Korean  patients  is  1.4～6.4%.  Thus,  MODY  3  is 
not rare in early-onset type 2 diabetes, and MODY mutations in 
patients  with  early-onset  type  2  diabetes  need  to  be  further 
evaluated.
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